Zoetis (ZTS) fundamentals: P/E, valuation, undervalued?
Zoetis · Health Care · ref. ETF XLV · price $75.02
In short — Zoetis trades at 12.7× earnings (P/E), 11.5× forward, with a net margin of 27.7 % and revenue growth of -0 %. Read: Low P/E (P/E 13 (below the ~20 market average)).
Is Zoetis stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$75.02-51.5% over range
Aug 28, 25low $71.86 · high $156.4Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
50% recommend buying · 12 analysts
Valuation : Low P/E — P/E 13 (below the ~20 market average)
Valuation
12.7
P/E (price/earnings)
11.5
Forward P/E
10.54
PEG
—
Price/book (P/B)
$31.0B
Market cap
5.93
EPS
Profitability & growth
27.7 %
Net margin
-0 %
Revenue growth
+1 %
Earnings growth
$9.3B
Total debt
Zoetis income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $8.1B | $2.1B | 26.2 % |
| 2023 | $8.5B | $2.3B | 27.4 % |
| 2024 | $9.3B | $2.5B | 26.9 % |
| 2025 | $9.5B | $2.7B | 28.2 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Zoetis's P/E and is the stock undervalued? What's a good P/E?
Zoetis's P/E is 12.7 (forward 11.5). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Low P/E".
Is Zoetis profitable?
Zoetis has a net margin of 27.7 % (EPS 5.93). The company is profitable.
Is ZTS stock expensive?
Our read: "Low P/E" — P/E 13 (below the ~20 market average). Cross-check with growth and sector.
💬 A question about Zoetis? The JPI assistant answers using our backtest data.